Evidence map›Paper›PMID 41425802›Full record

ArticleACS bio & med chem Au2025

1,2,4-Triazole-Based First-in-Class Non-Nucleoside Inhibitors of the Bacterial Enzyme MraY.

Tomayo Berida, Tzu-Yu Huang, Stefanie C Weck, Marcel Lutz, Samuel R McKee, Nathalie Kagerah, Destinee L Manning, Mohamed E Jahan, Sushil Mishra, Jennifer Herrmann and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS bio & med chem Au, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Tomayo BeridaDepartment of BioMolecular Sciences, University of Mississippi, University, Mississippi 38677, United States.ORCID https://orcid.org/0000-0002-3578-1033
Tzu-Yu HuangDepartment of BioMolecular Sciences, University of Mississippi, University, Mississippi 38677, United States.
Stefanie C WeckDepartment of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, and PharmaScienceHub (PSH), Saarbrücken 66123, Germany.
Marcel LutzDepartment of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, and PharmaScienceHub (PSH), Saarbrücken 66123, Germany.
Samuel R McKeeDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Nathalie KagerahDepartment of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, and PharmaScienceHub (PSH), Saarbrücken 66123, Germany.
Destinee L ManningDepartment of BioMolecular Sciences, University of Mississippi, University, Mississippi 38677, United States.ORCID https://orcid.org/0000-0001-7825-5896
Mohamed E JahanDepartment of BioMolecular Sciences, University of Mississippi, University, Mississippi 38677, United States.
Sushil MishraDepartment of BioMolecular Sciences, University of Mississippi, University, Mississippi 38677, United States.ORCID https://orcid.org/0000-0002-3080-9754
Jennifer HerrmannHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Department of Pharmacy, Saarland University, and PharmaScienceHub (PSH), Saarbrücken 66123, Germany.ORCID https://orcid.org/0000-0003-3398-9938
Rolf MüllerHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Department of Pharmacy, Saarland University, and PharmaScienceHub (PSH), Saarbrücken 66123, Germany.
Robert J DoerksenDepartment of BioMolecular Sciences, University of Mississippi, University, Mississippi 38677, United States.ORCID https://orcid.org/0000-0002-3789-1842
Christina L StallingsDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Christian DuchoDepartment of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, and PharmaScienceHub (PSH), Saarbrücken 66123, Germany.ORCID https://orcid.org/0000-0002-0629-9993
Sudeshna RoyDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee 38103, United States.ORCID https://orcid.org/0000-0003-0237-4156

Funding

Development of 1,2,4-Triazolyl Compounds and their derivatives as a New Treatment for TuberculosisR01AI181316 · NIAID · WASHINGTON UNIVERSITY · PI Sudeshna Roy, Christina Leigh Stallings · 2024 to 2026
$2.3M
NIAID NIH HHS R01 AI181316
6 · The paper itself

Abstract

MraY is an essential bacterial enzyme for peptidoglycan synthesis in cell walls and serves as a promising but unrealized target for developing effective antibacterial drugs. Nature has provided a remarkable array of nucleoside inhibitors of MraY, and researchers have skillfully refined these structures to develop inhibitors that effectively mimic natural products. Yet, both natural products and their synthetic variants often face challenges regarding inadequate

Indexed as

1,2,3-triazolesantibacterial agentsMraY inhibitorsnon-nucleoside inhibitorsstructure-based design

Identifiers

PMID41425802
PMCPMC12715639

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.